BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Elsevier B.V.
2014
|
| Online Access: | http://hdl.handle.net/1721.1/92489 https://orcid.org/0000-0001-8855-8647 |
| _version_ | 1811093180940025856 |
|---|---|
| author | Delmore, Jake E. Issa, Ghayas C. Lemieux, Madeleine E. Rahl, Peter B. Shi, Junwei Jacobs, Hannah M. Kastritis, Efstathios Gilpatrick, Timothy Paranal, Ronald M. Qi, Jun Chesi, Marta Schinzel, Anna C. McKeown, Michael R. Heffernan, Timothy P. Vakoc, Christopher R. Bergsagel, P. Leif Ghobrial, Irene M. Richardson, Paul G. Young, Richard A. Hahn, William C. Anderson, Kenneth C. Kung, Andrew L. Bradner, James E. Mitsiades, Constantine S. |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Delmore, Jake E. Issa, Ghayas C. Lemieux, Madeleine E. Rahl, Peter B. Shi, Junwei Jacobs, Hannah M. Kastritis, Efstathios Gilpatrick, Timothy Paranal, Ronald M. Qi, Jun Chesi, Marta Schinzel, Anna C. McKeown, Michael R. Heffernan, Timothy P. Vakoc, Christopher R. Bergsagel, P. Leif Ghobrial, Irene M. Richardson, Paul G. Young, Richard A. Hahn, William C. Anderson, Kenneth C. Kung, Andrew L. Bradner, James E. Mitsiades, Constantine S. |
| author_sort | Delmore, Jake E. |
| collection | MIT |
| description | MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation. Using a selective small-molecule bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc. BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic malignancy, JQ1 produces a potent antiproliferative effect associated with cell-cycle arrest and cellular senescence. Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc. |
| first_indexed | 2024-09-23T15:40:39Z |
| format | Article |
| id | mit-1721.1/92489 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T15:40:39Z |
| publishDate | 2014 |
| publisher | Elsevier B.V. |
| record_format | dspace |
| spelling | mit-1721.1/924892022-09-29T15:25:49Z BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Delmore, Jake E. Issa, Ghayas C. Lemieux, Madeleine E. Rahl, Peter B. Shi, Junwei Jacobs, Hannah M. Kastritis, Efstathios Gilpatrick, Timothy Paranal, Ronald M. Qi, Jun Chesi, Marta Schinzel, Anna C. McKeown, Michael R. Heffernan, Timothy P. Vakoc, Christopher R. Bergsagel, P. Leif Ghobrial, Irene M. Richardson, Paul G. Young, Richard A. Hahn, William C. Anderson, Kenneth C. Kung, Andrew L. Bradner, James E. Mitsiades, Constantine S. Massachusetts Institute of Technology. Department of Biology Young, Richard A. MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the function of the c-Myc oncoprotein do not exist. Toward this objective, we have targeted MYC transcription by interfering with chromatin-dependent signal transduction to RNA polymerase, specifically by inhibiting the acetyl-lysine recognition domains (bromodomains) of putative coactivator proteins implicated in transcriptional initiation and elongation. Using a selective small-molecule bromodomain inhibitor, JQ1, we identify BET bromodomain proteins as regulatory factors for c-Myc. BET inhibition by JQ1 downregulates MYC transcription, followed by genome-wide downregulation of Myc-dependent target genes. In experimental models of multiple myeloma, a Myc-dependent hematologic malignancy, JQ1 produces a potent antiproliferative effect associated with cell-cycle arrest and cellular senescence. Efficacy of JQ1 in three murine models of multiple myeloma establishes the therapeutic rationale for BET bromodomain inhibition in this disease and other malignancies characterized by pathologic activation of c-Myc. National Institutes of Health (U.S.) (NIH-K08CA128972) National Institutes of Health (U.S.) (NIH-R01CA050947) National Institutes of Health (U.S.) (NIH-R01HG002668) National Institutes of Health (U.S.) (NIH-R01CA46455) Massachusetts General Hospital (Chambers Medical Foundation) Harvard University (Stepanian Fund for Myeloma Research) Harvard University (Richard J. Corman Foundation) American Cancer Society (Postdoctoral Fellowship, 120272-PF-11-042-01-DMC) Burroughs Wellcome Fund Richard and Susan Smith Family Foundation Damon Runyon Cancer Research Foundation Multiple Myeloma Research Foundation 2014-12-23T21:15:23Z 2014-12-23T21:15:23Z 2011-09 Article http://purl.org/eprint/type/JournalArticle 00928674 http://hdl.handle.net/1721.1/92489 Delmore, Jake E., Ghayas C. Issa, Madeleine E. Lemieux, Peter B. Rahl, Junwei Shi, Hannah M. Jacobs, Efstathios Kastritis, et al. “BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc.” Cell 146, no. 6 (September 2011): 904–917. © 2011 Elsevier Inc. https://orcid.org/0000-0001-8855-8647 en_US http://dx.doi.org/10.1016/j.cell.2011.08.017 Cell Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. application/pdf Elsevier B.V. Elsevier |
| spellingShingle | Delmore, Jake E. Issa, Ghayas C. Lemieux, Madeleine E. Rahl, Peter B. Shi, Junwei Jacobs, Hannah M. Kastritis, Efstathios Gilpatrick, Timothy Paranal, Ronald M. Qi, Jun Chesi, Marta Schinzel, Anna C. McKeown, Michael R. Heffernan, Timothy P. Vakoc, Christopher R. Bergsagel, P. Leif Ghobrial, Irene M. Richardson, Paul G. Young, Richard A. Hahn, William C. Anderson, Kenneth C. Kung, Andrew L. Bradner, James E. Mitsiades, Constantine S. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title_full | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title_fullStr | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title_full_unstemmed | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title_short | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc |
| title_sort | bet bromodomain inhibition as a therapeutic strategy to target c myc |
| url | http://hdl.handle.net/1721.1/92489 https://orcid.org/0000-0001-8855-8647 |
| work_keys_str_mv | AT delmorejakee betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT issaghayasc betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT lemieuxmadeleinee betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT rahlpeterb betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT shijunwei betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT jacobshannahm betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT kastritisefstathios betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT gilpatricktimothy betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT paranalronaldm betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT qijun betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT chesimarta betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT schinzelannac betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT mckeownmichaelr betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT heffernantimothyp betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT vakocchristopherr betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT bergsagelpleif betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT ghobrialirenem betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT richardsonpaulg betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT youngricharda betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT hahnwilliamc betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT andersonkennethc betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT kungandrewl betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT bradnerjamese betbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT mitsiadesconstantines betbromodomaininhibitionasatherapeuticstrategytotargetcmyc |